Oncolytics Completes Patient Enrollment in U.K. Phase I Clinical Trial
Complete the form below to unlock access to ALL audio articles.
Oncolytics Biotech Inc. has announced that it has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies (REO 012).
"We are pleased to complete enrollment of this technical study examining cyclophosphamide's potential to modulate the immune system's response to REOLYSIN," said Dr. Matt Coffey , COO of Oncolytics.
Dr. Coffey continued, "Studies of this type help to advance our understanding of the interaction between the immune system and our product."
The primary objective of the open label, dose-escalating, non-randomized, 36-patient study is to determine the Minimum Effective Immunomodulatory Dose (MED) of cyclophosphamide necessary to obtain successful immune modulation.
Secondary objectives of the trial include assessing the safety profile of the combination and gathering any evidence of antitumor activity.
Eligible patients include those who have been diagnosed with advanced or metastatic solid tumors, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no standard curative therapy exists.
